Drug-Induced Liver Injury: Are We Ready to Look?; Public Conference; Request for Comments

Streszczenie

The Food and Drug Administration (FDA) is announcing a public conference entitled "Drug-Induced Liver Injury: Are We Ready to Look?" The public conference will be cosponsored with the American Association for the Study of Liver Diseases (AASLD) and the Pharmaceutical and Research Manufacturers of America to discuss and debate issues regarding drug-induced liver injury (DILI). The purpose of this conference is to consider the effect of the recommendations in the guidance for industry entitled "Drug-Induced Liver Injury: Premarketing Clinical Evaluation" since its publication in July 2009 and to seek suggestions for future revision.